Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.66 |
| ▸ | MTOR | P42345 | 20/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.52 |
| ▸ | ATR | Q13535 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3429543 | 0.93 | PIK3CA (0.66) | PIK3CAMTORPIK3CGPIK3CDPIK3CB | |
| SCHEMBL3432036 | 0.92 | PIK3CA (0.69) | PIK3CAMTORPIK3CGATR | |
| SCHEMBL3426609 | 0.90 | PIK3CA (0.79) | PIK3CAMTORPIK3CG | |
| SCHEMBL3407718 | 0.89 | PIK3CA (0.71) | PIK3CAMTORPIK3CGPIK3CDPIK3CB | |
| SCHEMBL3431520 | 0.89 | PIK3CA (0.69) | PIK3CAMTORPIK3CGPIK3CDPIK3CB | |
| SCHEMBL3429964 | 0.88 | PIK3CA (0.66) | PIK3CAMTORPIK3CG | |
| SCHEMBL3431178 | 0.88 | PIK3CA (0.63) | PIK3CAMTORPIK3CGATR | |
| SCHEMBL3429473 | 0.85 | PIK3CA (0.65) | PIK3CAMTORPIK3CGATR | |
| SCHEMBL3430224 | 0.85 | PIK3CA (0.61) | PIK3CAMTORPIK3CGATR | |
| SCHEMBL3406354 | 0.85 | PIK3CA (0.62) | PIK3CAMTORPIK3CGATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252296-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | Wyeth LLC (US) | 2010-11-24 | — | — | EP | claimed |
| WO-2009091788-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-23 | — | — | WO | claimed |
| US-20090181963-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-16 | — | — | US | claimed |
| EP-2254871-A1 | SALTS COMPRISING ARYL-ALKYL-SUBSTITUTED IMIDAZOLIUM AND TRIAZOLIUM CATIONS AS IONIC FLUIDS | Technische Universität Dresden (DE) | 2010-12-01 | — | — | EP | disclosed |
| EP-2252296-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | Wyeth LLC (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009095012-A1 | SALTS COMPRISING ARYL-ALKYL-SUBSTITUTED IMIDAZOLIUM AND TRIAZOLIUM CATIONS AND THE USE THEREOF | Technische Universität Dresden (DE) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009091788-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090181963-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181963-A1 | 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, PIK3CA, PIK3CD | PIK3CA 2/4885MTOR 1/4885PIK3CG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.